RxDoctor Payments Data

Ryan Klitgaard, MD

Family Medicine · Carrollton, TXNPI 1801240809

Payments from drug & device makers

$4,583in general payments, 2019–2025

Across 256 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$556
  • Novo Nordisk$493
  • AstraZeneca$358
  • Abbott$333
  • Pfizer$301
  • Lilly USA, LLC$272
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$4,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,583 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,925
Medicare patients
66
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$33,218
JardianceEmpagliflozin12$17,095
FarxigaDapagliflozin Propanediol17$11,541
Hydroxyzine Hcl20$676
Atorvastatin Calcium92$629
Duloxetine Hcl19$598
Albuterol Sulfate HfaAlbuterol Sulfate23$550
Losartan Potassium67$373
Rosuvastatin Calcium35$362
Tamsulosin Hcl20$359
Gabapentin16$304
Trazodone Hcl29$280
Omeprazole27$258
Metformin Hcl ErMetformin Hcl42$227
Amlodipine Besylate50$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$493$33,21826 claims
Boehringer IngelheimJardiance$91$17,09512 claims
AstraZenecaFarxiga$358$11,54117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →